Who is sponsoring NCT00087334?

NCT00087334 is sponsored by Roswell Park Cancer Institute.

What condition does NCT00087334 study?

NCT00087334 studies Colorectal Cancer.

What drugs are being tested in NCT00087334?

Interventions: capecitabine, gefitinib, oxaliplatin.

What is the status of NCT00087334?

NCT00087334 is currently TERMINATED.

Last reviewed 2013-01-31 · How we verify

A Phase I/II Study of Capecitabine (XELODA®, Roche) Plus Oxaliplatin (Eloxatin®, Sanofi) Plus ZD 1893 (IRESSA®) in the Treatment of Metastatic Colorectal Cancer

NCT00087334 Phase 1/Phase 2 TERMINATED

RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining capecitabine and oxaliplatin with gefitinib may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of capecitabine when given together with oxaliplatin and gefitinib and to see how well they work in treating patients with metastatic colorectal cancer.

Details

Lead sponsor	Roswell Park Cancer Institute
Phase	Phase 1/Phase 2
Status	TERMINATED
Enrolment	10
Start date	2004-01

Conditions

Colorectal Cancer

Interventions

capecitabine
gefitinib
oxaliplatin

Primary outcomes

Maximum tolerated dose
Response rate

Countries

United States